GLP-1 medications like Ozempic, Wegovy, and Mounjaro are some of the most talked-about drugs in the world right now. But how do they actually work, and what’s really going on behind the scenes?
In this episode, we break down the science of GLP-1 receptor agonists in plain English, including how they affect appetite, insulin, gastric emptying, and long-term weight loss. We also review clinical trial data, real-world outcomes, and what happens when people stop taking these medications.
Then we go deeper into the part most people aren’t talking about: drug shortages, compounded GLP-1 alternatives, and the rapidly growing gray market. We explain how compounding pharmacies operate during FDA-declared shortages, what “copycat” or “bootleg” versions really are, and where the legal lines start to blur.
We also discuss recent FDA actions, enforcement trends, and the broader pharmaceutical landscape, including pricing, patents, and why these drugs have become such a massive financial battleground. From stock volatility to regulatory pressure, there’s more going on here than just weight loss.
If you’ve been hearing about GLP-1 drugs everywhere and want a clear, honest explanation of both the science and the controversy, this episode gives you the full picture.